A judge has upheld Neurim Pharmaceuticalâs claim for additional damages against two generic drug companies found to have infringed its patent for insomnia drug Circadin, despite the company’s failure to comply with an earlier ruling.
Convenience chain 7-Eleven has defeated Seven Network’s challenge to its bid to trade mark ‘7-Select’ for a new brand of products targeting younger shoppers, with an IP Australia delegate finding consumer confusion was not likely.
After a seven-year legal battle, a court has upheld the validity of Neurim Pharmaceuticalâs patent for insomnia drug Circadin and ruled two generic drug companies infringed the intellectual property.
The sole director of a small software company can’t act for his business in defending against an intellectual property case brought by digital titan Google, despite his plea to the court that his firm did not have the financial means to hire lawyers.
Construing an âambiguousâ order from the Full Federal Court, a judge has ordered a fresh trial in a trade secrets case that touched on the permissible scope of law firmsâ involvement in drafting expert reports.
Novartis unit Sandoz has won its bid to stay a case by rival Lundbeck, including orders for damages previously calculated at $26.3 million and counting, despite having succeeded at the High Court in a dispute over its patent for blockbuster antidepressant Lexapro.
Skincare giant LâOreal has lost the rights to use a 23-year-old trade mark for branding some of its products, after a competitor successfully campaigned IP Australia to strike it from the register for non-use.Â
An appeals court has said that while it might be desirable for law firms to disclose their involvement in drafting expert reports, they are not legally obligated to do so, overturning a finding that Corrs Chambers Westgarth went âfar beyond the permissible scopeâ of involvement in a report prepared for a trade secrets case.
American fast food chain In-N-Out Burgers has won an injunction against a Queensland ‘ghost kitchen’ that operates solely through meal delivery apps, after it failed to comply with court-ordered undertakings.
Israeli drug company Neurim Pharmaceuticals has lost a bid to patent a mini version of its melatonin tablet Circadin for children, after a successful challenge by Australian drug maker Generic Partners.